The partnership combines RRG’s FDA-registered, CLIA-certified laboratory and industry-leading biologic products with ...

February 19-22 event in Sarasota, Florida features hands-on ultrasound training and sessions on emerging biologics, ...

GLP-1 therapies are a cornerstone for the management of type 2 diabetes, supporting glycemic control and improving ...

"Understanding biologic therapy trajectories in Medicaid is important, given its distinct formulary restrictions and patient demographics," they concluded. "Interventions must not only address access ...

On Aug. 29, Medicare released its highly anticipated list of 10 therapies for which it plans to establish a price by 2026. The Inflation Reduction Act (IRA), passed in August 2022, gives Medicare ...

In the latest trading session, Adma Biologics (ADMA) closed at $16.32, marking a +2.06% move from the previous day. This move outpaced the S&P 500's daily loss of 0.28%. Meanwhile, the Dow lost 0.54%, ...

The Nobel Prize in Medicine will never be awarded for excellence in the formulation and manufacture of biologic medicines. That’s understandable. Patients who need these medicines deserve the product ...

So far this year, medtech companies and academic institutions are making key strides in spine biologics. From new product launches to research breakthroughs, here are the biggest developments to know: ...

SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization of biologics. A suite of five built-in workflows, optimized for CID and ...

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - ...

Shreehas Tambe, MD & CEO of Biocon Biologics, said the company expects its margins to remain in the mid-20% range for the full year, guided at around 24% to 26%.

The beginning of 2026 has been characterized by volatility in equities. Amidst this, the S&P 500 Index ($SPX) has remained sideways. While the technology sector dominated headlines last year, it might ...